How to buy Moderna shares | $69.47

Moderna, Inc is a biotechnology business with stocks listed in the US. Moderna shares (MRNA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$69.47 – an increase of 0.3% over the previous week.

How to buy shares in Moderna

1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
3. Search for Moderna. Find the share by name or ticker symbol: MRNA. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Moderna reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of US$69.47, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Moderna, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Moderna. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Moderna share price

Use our graph to track the performance of MRNA stocks over time.

Moderna shares at a glance

• Key figures

Information last updated 2020-09-25.

Latest market close	USD$69.47
52-week range	USD$13.53 - USD$95.21
50-day moving average	USD$66.5003
200-day moving average	USD$57.7545
Target price	USD$92.54
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.348

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

eToro Share Trading (US stocks)

USD 0

Standard brokerage - US shares

Get $0 brokerage on US stocks with trades as little as $50 when you join the world’s biggest social trading network.

• $0 brokerage for US stocks
• Trades starting from $50
• Fractional shares
• Copy top traders

Go to site

More info

Important: Share trading carries risk of capital loss.

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Moderna stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Moderna, Inc by TradingView

Moderna price performance over time

Historical closes compared with the close of $69.47 on 2020-09-25

1 week (2020-09-24)	6.60%
1 month (2020-09-01)	9.71%
3 months (2020-07-01)	12.79%
6 months (2020-04-01)	134.14%

1 year (2019-10-01)	369.07%
2 years (2018-09-27)	N/A
3 years (2017-09-27)	N/A
5 years (2015-09-27)	N/A

Moderna financials

Revenue TTM	US$105.8 million
Gross profit TTM	US$-436,100,000
Return on assets TTM	-12.41%
Return on equity TTM	-22.75%
Profit margin	0%
Book value	7.493
Market capitalisation	US$27.2 billion

TTM: trailing 12 months

Shorting Moderna shares

There are currently 28.0 million Moderna shares held short by investors – that's known as Moderna's "short interest". This figure is 11.5% down from 31.7 million last month.

There are a few different ways that this level of interest in shorting Moderna shares can be evaluated.

Moderna's "short interest ratio" (SIR)

Moderna's "short interest ratio" (SIR) is the quantity of Moderna shares currently shorted divided by the average quantity of Moderna shares traded daily (recently around 13.9 million). Moderna's SIR currently stands at 2.02. In other words for every 100,000 Moderna shares traded daily on the market, roughly 2020 shares are currently held short.

However Moderna's short interest can also be evaluated against the total number of Moderna shares, or, against the total number of tradable Moderna shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moderna's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Moderna shares in existence, roughly 70 shares are currently held short) or 0.0925% of the tradable shares (for every 100,000 tradable Moderna shares, roughly 93 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moderna.

Find out more about how you can short Moderna stock.

Moderna share dividends

We're not expecting Moderna to pay a dividend over the next 12 months.

Moderna overview

Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation; and a research collaboration with Harvard University. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of mRNA-1273, a COVID-19 vaccine; and Catalent for fill-finish manufacturing of its COVID-19 vaccine candidate. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

• What percentage of Moderna is owned by insiders or institutions?

  Currently 23.942% of Moderna shares are held by insiders and 53.532% by institutions.

• When does the fiscal year end for Moderna?

  Moderna's fiscal year ends in December.

• Where is Moderna based?

  Moderna's address is: 200 Technology Square, Cambridge, MA, United States, 02139

• What is Moderna's ISIN number?

  Moderna's international securities identification number is: US56804Q2012

• What is Moderna's CUSIP number?

  Moderna's Committee on Uniform Securities Identification Procedures number is: 56804Q201